一种针对冠心病患者的风险消除智能个体化心血管应用程序(iCARE)卡塔尔世界杯8强波胆分析开发与可用性测试分析[A]陈a， [A]姬玉玲，[A]吴美华，[A]王莹，[A]邓青玉，[A]刘莹，[A]吴勇，[A]刘芳琴，[A]郭明轩，[A]傅义强，[A]郑子媛，[A]小瑛]首都医科大学护理学院，北京市丰台区友安门外西头条10号，100069，中国，86 83911766;helenywu@vip.163.com %K移动健康%K健康行为%K系统%K发展%K可用性%K冠心病%D 2021 %7 13.12.2021 %9原文Mhealth Uhealth背景:通过改善危险因素管理，可以在很大程度上降低冠心病(CHD)的死亡和残疾。然而，坚持以证据为基础的建议具有挑战性，需要在患者、提供者和卫生系统层面进行干预。目的:本研究旨在开发一款智能个体化心血管风险消除应用程序(iCARE)，以促进健康行为和预防药物的依从性，并测试iCARE的可用性。方法:我们基于以用户为中心的设计方法开发了iCARE，包括4个阶段:(1)功能设计，(2)迭代设计，(3)专家检查和原型演练，以及(4)最终用户可用性测试。iCARE的可用性测试包括两个阶段:第一阶段，包括使用修改后的健康信息技术可用性调查(Health- itues)对iCARE患者应用程序进行任务分析和可用性评估(2019年1月至3月);第二阶段(2020年6月)，在使用该应用程序6个月的最终用户中使用Health-ITUES。最终用户为中国北京两所大学附属医院确诊的冠心病患者。结果:iCARE由患者应用、医护人员应用和云平台组成。 It has a set of algorithms that trigger tailored feedback and can send individualized interventions based on data from initial assessment and health monitoring via manual entry or wearable devices. For stage I usability testing, 88 hospitalized patients (72% [63/88] male; mean age 60 [SD 9.9] years) with CHD were included in the study. The mean score of the usability testing was 90.1 (interquartile range 83.3-99.0). Among enrolled participants, 90% (79/88) were satisfied with iCARE; 94% (83/88) and 82% (72/88) reported that iCARE was useful and easy to use, respectively. For stage II usability testing, 61 individuals with CHD (85% [52/61] male; mean age 53 [SD 8.2] years) who were from an intervention arm and used iCARE for at least six months were included. The mean total score on usability testing based on the questionnaire was 89.0 (interquartile distance: 77.0-99.5). Among enrolled participants, 89% (54/61) were satisfied with the use of iCARE, 93% (57/61) perceived it as useful, and 70% (43/61) as easy to use. Conclusions: This study developed an intelligent, individualized, evidence-based, and theory-driven app (iCARE) to improve patients’ adherence to health behaviors and medication management. iCARE was identified to be highly acceptable, useful, and easy to use among individuals with a diagnosis of CHD. Trial Registration: Chinese Clinical Trial Registry ChiCTR-INR-16010242; https://tinyurl.com/2p8bkrew %M 34898449 %R 10.2196/26439 %U https://mhealth.www.mybigtv.com/2021/12/e26439 %U https://doi.org/10.2196/26439 %U http://www.ncbi.nlm.nih.gov/pubmed/34898449